In-field assay monitoring of anti-HIV-1/HIV-2 EIAs in Australian Blood Banks, 1992. Australian Red Cross Blood Transfusion Service Laboratories.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

In-field assay monitoring of anti-HIV-1/HIV-2 EIAs in Australian Blood Banks, 1992. Australian Red Cross Blood Transfusion Service Laboratories.

Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:111 (poster no. 72). Unique Identifier : AIDSLINE ASHM5/94348931
Dax EM; Bendistinto M; Vandenbelt T; National HIV Reference Laboratory (NRL), Fairfield Hospital,; Victoria, Australia.

Abstract: OBJECTIVE: To examine the performance of 4 anti-HIV-1/HIV-2 enzyme immunoassays (EIAs) in Australian Blood Banks during use. EIAs included: Abbott Recombinant, Diagnostic Pasteur Genelavia MIXT, Genetic Systems EIA and Organon Teknika. METHODS: Anti-HIV-1/HIV-2 EIAs were monitored by collecting data from individual laboratories each month. The data included number of specimens tested, number of specimens found to be initially reactive, and repeatably reactive per week. Assay batch numbers were also recorded. Data were relayed to the NRL as part of the regular assay monitoring procedures used in the quality assurance program in Australia. Initial (IRR) and repeat reactor rates (RRR) were calculated for each assay and batch. Overall mean 'in-field' specificities (Sp.) were calculated as 100-RRR% and compared with evaluation specificities (Eval. Sp.) found during formal evaluation using 5000 fresh donations for each assay. RESULTS: The Genetic Systems EIA showed the least variation between batches (N = 4) while others demonstrated 3-4 fold variation in RRR. The Organon and Pasteur batches showed large variation between IRR and RRR, suggesting that these EIAs are prone to technical error. (see table below) CONCLUSION: Three of the HIV-1/HIV-2 EIAs demonstrated 'in-field' specificity within the evaluation specificity range. TABULAR DATA, SEE ABSTRACT VOLUME.

Keywords: Australia *Blood Banks *Blood Transfusion Human HIV Infections/*PREVENTION & CONTROL/TRANSMISSION HIV-1/*ISOLATION & PURIF HIV-2/*ISOLATION & PURIF *Immunoenzyme Techniques Mass Screening Quality Control Red Cross ABSTRACT
941230
M94C4296

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .